Novo Nordisk A/S (NYSE:NVO) Shares Sold by LRT Capital Management LLC

LRT Capital Management LLC trimmed its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 44.6% in the 4th quarter, HoldingsChannel reports. The firm owned 3,971 shares of the company’s stock after selling 3,196 shares during the quarter. LRT Capital Management LLC’s holdings in Novo Nordisk A/S were worth $342,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of NVO. Diversified Trust Co boosted its holdings in shares of Novo Nordisk A/S by 13.9% in the fourth quarter. Diversified Trust Co now owns 3,246 shares of the company’s stock worth $279,000 after buying an additional 395 shares during the period. ORG Partners LLC raised its holdings in shares of Novo Nordisk A/S by 181.7% during the fourth quarter. ORG Partners LLC now owns 1,003 shares of the company’s stock valued at $86,000 after acquiring an additional 647 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Novo Nordisk A/S by 0.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 290,489 shares of the company’s stock valued at $24,988,000 after acquiring an additional 1,051 shares in the last quarter. Fiduciary Alliance LLC boosted its stake in Novo Nordisk A/S by 11.4% in the 4th quarter. Fiduciary Alliance LLC now owns 8,107 shares of the company’s stock worth $697,000 after purchasing an additional 829 shares during the period. Finally, Capital Investment Advisors LLC grew its position in Novo Nordisk A/S by 12.1% during the 4th quarter. Capital Investment Advisors LLC now owns 4,435 shares of the company’s stock worth $382,000 after purchasing an additional 478 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on NVO. BMO Capital Markets restated a “market perform” rating and issued a $64.00 target price (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 25th. Guggenheim downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Finally, Dbs Bank lowered shares of Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. Two investment analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $135.00.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO opened at $65.75 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The business’s 50-day moving average price is $69.21 and its two-hundred day moving average price is $85.83. The company has a market capitalization of $295.06 billion, a P/E ratio of 19.98, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, meeting the consensus estimate of $0.92. The business had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $79.17 billion. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.